Author: "Leboeuf, Christophe" / Topic: [sdv.mhep.csc]life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Leboeuf, Christophe"' showing total 32 results

Start Over Author "Leboeuf, Christophe" Topic [sdv.mhep.csc]life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system

32 results on '"Leboeuf, Christophe"'

1. Genomics applied to the treatment of breast cancer

Author: Hamdan, Diaddin, Nguyen, Thi Thuy Nga, Leboeuf, Christophe, Meles, Solveig, Janin, Anne, Bousquet, Guilhem, Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord, Hôpital de La Porte Verte, National Cancer Hospital [Ha Noi, Viet Nam], Hanoï Medical University, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Université Sorbonne Paris Nord, Ratajczak, Philippe, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord
Subjects: MESH: constitutional genomics, genomics applied to treatment, genomics of breast cancer, molecular and histological classification, tumor heterogeneity, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Review, constitutional genomics, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.BIO] Life Sciences [q-bio]/Biotechnology, [SDV.TOX] Life Sciences [q-bio]/Toxicology, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.TOX]Life Sciences [q-bio]/Toxicology
Abstract: International audience; Breast cancer remains a major health issue in the world with 1.7 million new cases in 2012 worldwide. It is the second cause of death from cancer in western countries. Genomics have started to modify the treatment of breast cancer, and the developments should become more and more significant, especially in the present era of treatment personalization and with the implementation of new technologies. With molecular signatures, genomics enabled a de-escalation of chemotherapy and personalized treatments of localized forms of estrogen-dependent breast cancers. Genomics can also make a real contribution to constitutional genetics, so as to identify mutations in a panel of candidate genes. In this review, we will discuss the contributions of genomics applied to the treatment of breast cancer, whether already validated contributions or possible future applications linked to research data.
Published: 2019

2. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)

Author: Javed Butler, Adrian F. Hernandez, Paul W. Armstrong, Justin A. Ezekowitz, Piotr Ponikowski, Cynthia M. Westerhout, Vojtěch Melenovský, Burkert Pieske, Ciaran McMullan, Yinggan Zheng, Adriaan A. Voors, Jorge Escobedo, Christopher DeFilippi, Lothar Roessig, Carolyn S.P. Lam, Christopher M. O'Connor, Alain Cohen-Solal, leboeuf, Christophe, University of Alberta, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Institute of Clinical and Experimental Medicine [Prague, Czech Republic] (ICEM), Mexican Social Security Institute [Mexico City] (M2SI), University of Mississippi Medical Center (UMMC), Duke University Medical Center, Duke-National University of Singapore Graduate Medical School, Inova Heart and Vascular Institute [Falls Church, VA, USA] (IHVI), Berlin Institute of Health (BIH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Wrocław Medical University, University of Groningen [Groningen], Merck & Co., Inc. [Kenilworth, NJ, États-Unis], Bayer AG [Wuppertal, Germany], and Cardiovascular Centre (CVC)
Subjects: Male, medicine.medical_specialty, Anemia, vericiguat, heart failure, World Health Organization, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Physiology (medical), Internal medicine, medicine, Humans, In patient, hemoglobins, Aged, Ejection fraction, business.industry, Stroke Volume, medicine.disease, anemia, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Treatment Outcome, Heart failure, Cardiology, Vericiguat, Female, Hemoglobin, Cardiology and Cardiovascular Medicine, business
Abstract: Background: In the VICTORIA trial (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction), anemia occurred more often in patients treated with vericiguat (7.6%) than with placebo (5.7%). We explored the association between vericiguat, randomization hemoglobin, development of anemia, and whether the benefit of vericiguat related to baseline hemoglobin. Methods: Anemia was defined as hemoglobin Results: At baseline, 1719 (35.7%) patients had World Health Organization anemia; median hemoglobin was 13.4 g/L (25th, 75th percentile: 12.1, 14.7 g/dL). At 16 weeks from randomization, 1643 patients had World Health Organization anemia (284 new for vericiguat and 219 for placebo), which occurred more often with vericiguat than placebo ( P Conclusions: Anemia was common at randomization and lower hemoglobin was associated with a greater frequency of clinical events. Although vericiguat modestly lowered hemoglobin by 16 weeks, this effect did not further progress nor was it related to the treatment benefit of vericiguat. Registration: URL: https://www.clinicaltrials.gov : Unique identifier: NCT02861534.
Published: 2021

3. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials

Author: Olav W. Nielsen, Aldo P. Maggioni, Christopher L. Edwards, Marco Metra, Naoki Sato, Barry H. Greenberg, Faiez Zannad, Gad Cotter, Alexandre Mebazaa, Georg Ertl, Beth A. Davison, Alain Cohen-Solal, Ovidiu Chioncel, Stefanie Senger, John R. Teerlink, Momentum Research Inc. [Durham, NC, USA] (MRI), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, University of California [San Francisco] (UC San Francisco), University of California (UC), Veterans Affairs Medical Center, San Francisco, California, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), IT University of Copenhagen (ITU), Università degli Studi di Brescia = University of Brescia (UniBs), Civic Hospital of Brescia, Service d'Anesthésie-Réanimation [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), University of California [San Diego] (UC San Diego), Associazione Nazionale Medici Cardiologi Ospedalieri [Firenze] (ANMCO), University of Würzburg = Universität Würzburg, Nippon Medical School [Tokyo, Japon], Hôpital Lariboisière-Fernand-Widal [APHP], and leboeuf, Christophe
Subjects: medicine.medical_specialty, 030204 cardiovascular system & hematology, Glucagon-Like Peptide-1 Receptor, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Heart Failure, Humans, Hypoglycemic Agents, Regression Analysis, Sodium-Glucose Transporter 2 Inhibitors, Treatment Outcome, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Diabetes Mellitus, medicine, Treatment effect, 030212 general & internal medicine, business.industry, medicine.disease, Random effects model, Differential effects, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Heart failure, Cardiology and Cardiovascular Medicine, business, Type 2, Mace
Abstract: International audience; Background In international trials, glucagon-like protein-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were effective in improving cardiovascular (CV) outcomes. Methods We assessed the effect of GLP-1RAs and SGLT2Is treatment effect on CV endpoints by geographical region in multiple international trials using random effects weighted least squares meta-regressions. Results The estimated effects of both SGLT2Is and GLP-1RAs on major adverse CV events (MACE) in North America (SGLT2Is n = 12,399, HR 0.90, 95% CI 0.81-1.01; GLP-1RAs n = 12,515, HR 0.95, 95% CI 0.83-1.09) and in Europe (SGLT2Is n = 19,435, HR 0.93, 95% CI 0.85-1.02; GLP-1RAs n = 22,812, HR 0.88, 95% CI 0.79-0.99) were numerically lower but not statistically different to the rest of the world (ROW) (SGLT2Is n = 15,127, HR 0.83, 95% CI 0.75-0.92, p-value for interaction 0.26; GLP-1RAs n = 17,494, HR 0.82, 95% CI 0.73-0.92, p-value for interaction 0.28). Effects of SGLT2Is on heart failure readmission or CV death varied significantly by region (P = 0.0094). The effect of SGLT2Is was significantly smaller in Europe (n = 18,653, HR 0.86, 95% CI 0.78-0.95) than in the ROW (n = 12,463, HR 0.68, 95% CI 0.61-0.76, P = 0.0024). The smaller effect in North America (n = 9776, HR 0.76, 95% CI 0.66-0.87) did not differ significantly from that in the ROW (P = 0.2370). Conclusion The effects of SGLT2Is on HF events are larger in the ROW. Further analyses and studies are needed to better elucidate the differential effects of SGLTIs and GLP-1RAs by geographical regions.
Published: 2021

4. Iron deficiency in pulmonary arterial hypertension: perspectives

Author: Marceau Quatredeniers, Frédéric Perros, Alain Cohen-Solal, David Montani, Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay, Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and leboeuf, Christophe
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Anemia, Diseases of the respiratory system, Right heart failure, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Hepcidin, Internal medicine, medicine, Diseases of the circulatory (Cardiovascular) system, RC705-779, Ventricular function, biology, business.industry, right heart failure, iron supplementation, Treatment options, Iron deficiency, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Editorial, RC666-701, Cardiology, biology.protein, Iron supplementation, hepcidin, business, Rare disease
Abstract: International audience; In left heart failure, iron supplementation (IS) is a first-line treatment option, regardless of anemia. Pulmonary arterial hypertension (PAH), a rare disease leading to right heart failure, is also associated with iron deficiency. While it is a much debated topic, recent evidence demonstrate that restoration of iron stores results in improved right ventricular function and exercise tolerance. Hence, IS may also be considered as an option in the treatment of PAH.
Published: 2021

5. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure with Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial

Author: Lewis, Gregory, Voors, Adriaan, Cohen-Solal, Alain, Metra, Marco, Whellan, David, Ezekowitz, Justin, Böhm, Michael, Teerlink, John, Docherty, Kieran, Lopes, Renato, Divanji, Punag, Heitner, Stephen, Kupfer, Stuart, Malik, Fady, Meng, Lisa, Wohltman, Amy, Felker, G. Michael, Cardiovascular Centre (CVC), leboeuf, Christophe, Massachusetts General Hospital [Boston], University Medical Center Groningen [Groningen] (UMCG), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Università degli Studi di Brescia = University of Brescia (UniBs), Jefferson (Philadelphia University + Thomas Jefferson University), University of Glasgow, Saarland University [Saarbrücken], University of California [San Francisco] (UC San Francisco), University of California (UC), Veterans Affairs Medical Center, San Francisco, California, Universidade Estadual de Campinas = University of Campinas (UNICAMP), Cytokinetics Inc. [South San Francisco, CA, USA] (CI), and Duke University [Durham]
Subjects: Male, Heart Failure, Exercise Tolerance, Left, Cardiovascular Agents, Stroke Volume, General Medicine, Middle Aged, Ventricular Function, Left, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Ventricular Dysfunction, Left, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Double-Blind Method, Chronic Disease, Ventricular Dysfunction, Aged, Female, Humans, Urea, Ventricular Function, Original Investigation
Abstract: Importance: Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF) but is not consistently improved by any of the current guideline-directed medical therapies.Objective: To determine whether omecamtiv mecarbil, a novel direct myosin activator that improves cardiac performance and reduces the risk for cardiovascular death or first HF event in HFrEF, can improve peak exercise capacity in patients with chronic HFrEF.Design, Setting, and Participants: Phase 3, double-blind, placebo-controlled randomized trial of patients with HFrEF (left ventricular ejection fraction ≤35%), New York Heart Association class II-III symptoms, N-terminal pro-B-type natriuretic peptide level of 200 pg/mL or greater, and baseline peak oxygen uptake (Vo2) of 75% or less of predicted. Patients were randomized in a 2:1 ratio (omecamtiv mecarbil to placebo) between March 2019 and May 2021 at 63 sites in North America and Europe, with the last patient visit occurring on November 29, 2021.Interventions: Omecamtiv mecarbil (n = 185) or matching placebo (n = 91), given orally twice daily at a dose of 25 mg, 37.5 mg, or 50 mg based on target plasma levels, for 20 weeks.Main Outcomes and Measures: The primary end point was a change in exercise capacity (peak Vo2) from baseline to week 20. Secondary end points included total workload, ventilatory efficiency, and daily physical activity as determined by accelerometry.Results: Among 276 patients who were randomized (median age, 64 years; IQR, 55-70 years; 42 women [15%]), 249 (90%) completed the trial. The median left ventricular ejection fraction was 28% (IQR, 21-33) and the median baseline peak Vo2was 14.2 mL/kg/min (IQR, 11.6-17.4) in the omecamtiv mecarbil group and 15.0 mL/kg/min (IQR, 12.0-17.2) in the placebo group. Mean change in peak Vo2did not differ significantly between the omecamtiv mecarbil and placebo groups (mean, -0.24 mL/kg/min vs 0.21 mL/kg/min; least square mean difference, -0.45 mL/kg/min [95% CI, -1.02 to 0.13]; P =.13). Adverse events included dizziness (omecamtiv mecarbil: 4.9%, placebo: 5.5%), fatigue (omecamtiv mecarbil: 4.9%, placebo: 4.4%), heart failure events (omecamtiv mecarbil: 4.9%, placebo: 4.4%), death (omecamtiv mecarbil: 1.6%, placebo: 1.1%), stroke (omecamtiv mecarbil: 0.5%, placebo: 1.1%), and myocardial infarction (omecamtiv mecarbil: 0%, placebo: 1.1%).Conclusions and Relevance: In patients with chronic HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. These findings do not support the use of omecamtiv mecarbil for treatment of HFrEF for improvement of exercise capacity.Trial Registration: ClinicalTrials.gov Identifier: NCT03759392.
Published: 2022

6. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

Author: Michele Senni, Jose Lopez‐Sendon, Alain Cohen‐Solal, Piotr Ponikowski, Richard Nkulikiyinka, Cecilia Freitas, Vanja Miodrag Vlajnic, Lothar Roessig, Burkert Pieske, Hospital Papa Giovanni XXIII (Hosp P Giovanni XXIII), Universidad Autónoma de Madrid (UAM), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Service de cardiologie (APHP-Hôpital Lariboisière), Hôpital Lariboisière-APHP, University of Wrocław [Poland] (UWr), Bayer AG [Wuppertal, Germany], Bayer Pharma AG [Berlin], Bayer HealthCare Pharmaceuticals Inc [Whippany], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], German Heart Institute Berlin [Berlin, Germany] (GHIB), and leboeuf, Christophe
Subjects: [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, NT-proBNP, Heart failure, Cardiology and Cardiovascular Medicine, Heart failure with reduced ejection fraction, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Abstract: International audience; Aims Treatment response to vericiguat, based on baseline N-terminal pro-brain natriuretic peptide (NT-proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1-Q3] vs. the upper quartile [Q4]. Methods and results VICTORIA participants with available baseline NT-proBNP levels (n = 4805; 95.1% of total) were included. Compared with patients in Q1-Q3 (NT-proBNP: Q1, ≤1556 pg/mL; Q2, >1556-2816 pg/mL; and Q3, >2816-5314 pg/mL), patients in Q4 (NT-proBNP: >5314 pg/mL) were older (69.2 ± 12.0 vs. 66.6 ± 12.1 years), had lower mean ejection fraction (27.2 ± 8.3% vs. 29.5 ± 8.2%; P < 0.0001), and were more likely to be in New York Heart Association (NYHA) Class III (51.8 vs. 35.6%) or IV (2.4 vs. 1.0%). Compared with Q1-Q3, patients in Q4 had higher mean Meta-Analysis Global Group in Chronic Heart Failure risk score (27.3 ± 6.6 vs. 23.5 ± 6.4; P < 0.0001), had lower mean estimated glomerular filtration rate (eGFR; 51.5 ± 25.5 vs. 65.0 ± 26.8 mL/min/1.73 m 2 ; P < 0.0001) and haemoglobin (12.8 ± 2.0 vs. 13.6 ± 1.9 g/dL; P < 0.0001), and more had atrial fibrillation (48.7% vs. 43.1%; P = 0.0007) and were randomized while hospitalized for HF (14.8 vs. 9.9%; P < 0.0001). Target dose was achieved in 72.3 and 63.7% of patients in Q1-Q3 and Q4, respectively (P < 0.0001). Primary outcome (composite of time to cardiovascular death or first HF hospitalization) rates were 24.5 and 31.7 per 100 patient-years for vericiguat and placebo in Q1-Q3 [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.69-0.88, P < 0.001] and 73.6 and 63.6 in Q4 (HR 1.15; 95% CI 0.99-1.34, P = 0.070). Serious adverse events were more frequent in NT-proBNP Q4 (total population) compared with Q1-Q3 (38.3 vs. 32.3%; P = 0.0001), driven mainly by the placebo group. Adverse events leading to death were more frequent in Q4 than Q1-Q3 (5.8 vs. 2.4%; P < 0.0001). Conclusions Plasma NT-proBNP may help identify patients with worsening HF with reduced ejection fraction, in whom the beneficial effects of vericiguat may be highest. Patients with highest NT-proBNP values are probably too far advanced, suffering more co-morbidities, or still clinically unstable after decompensation to derive benefit from vericiguat.
Published: 2022

7. proANP Metabolism Provides New Insights Into Sacubitril/Valsartan Mode of Action

Author: Thibault Michel, Hélène Nougué, Jérôme Cartailler, Guillaume Lefèvre, Malha Sadoune, François Picard, Alain Cohen-Solal, Damien Logeart, Jean-Marie Launay, Nicolas Vodovar, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Département d’Anesthésie-Réanimation-SMUR [Hôpital Lariboisière], Hôpitaux Universitaire Saint-Louis, Lariboisière, Fernand-Widal, Institute of Chemistry for Life and Health Sciences (iCLeHS), Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand-Widal, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and leboeuf, Christophe
Subjects: Heart Failure, CD13 antigens, Physiology, Aminobutyrates, Biphenyl Compounds, endothelin-converting enzymes, Stroke Volume, neprilysin, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Drug Combinations, MicroRNAs, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, endothelin-1, Valsartan, Neprilysin, Hypotension, Cardiology and Cardiovascular Medicine, humans, atrial natriuretic factor
Abstract: Background: Sacubitril/valsartan (S/V) treatment is beneficial in patients with heart failure with reduced ejection fraction (HFrEF), but its mode of action remains elusive, although it involves the increase in ANP (atrial natriuretic peptide). Methods: Combining mass spectrometry and enzymatic assay in the plasma of 73 HFrEF patients treated with S/V and controls, we deciphered proANP processing that converts proANP into 4 vasoactive peptides. Results: We found that proANP processing is sequential and involved meprin B, ECE (endothelin-converting enzyme) 1, and ANPEP (aminopeptidase N). This processing is limited in HFrEF patients via the downregulation of proANP production, corin, and meprin B activities by miR-425 and miR1-3p. S/V restored or compensated proANP processing by downregulating miR-425 and miR1-3p, hence increasing levels of proANP-derived bioactive peptides. In contrast, S/V directly and indirectly partially inhibited ECE1 and ANPEP. ECE1 partial inhibition resulted in a lower-than-expected increase in ET1 (endothelin 1), tilting the vasoactive balance toward vasodilation, and possibly hypotension. Furthermore, proANP glycosylation interferes with the midregional proANP assay –a clinical surrogate for proANP production, preventing any pathophysiological interpretation of the results. The analysis of S/V dose escalation with respect to baseline treatments suggests S/V-specific effects. Conclusions: These findings offer mechanistic evidence to the natriuretic peptide -defective state in HFrEF, which is improved by S/V. These data also strongly suggests that S/V increases plasma ANP by multiple mechanisms that involve 2 microRNAs, besides its protection from NEP (neprilysin) cleavage. Altogether, these data provide new insights on HFrEF pathophysiology and the mode of action of S/V.
Published: 2022

8. Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?

Author: Andrew Sindone, Wolfram Doehner, Nicolas Manito, Theresa McDonagh, Alain Cohen-Solal, Thibaud Damy, Julio Núñez, Otmar Pfister, Peter van der Meer, Josep Comin-Colet, Concord Repatriation General Hospital [Sydney, Australia] (CRGH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), University of Barcelona, Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), King‘s College London, Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, CHU Henri Mondor, Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Universitat de València (UV), University of Basel (Unibas), University Hospital Basel [Basel], University Medical Center Groningen [Groningen] (UMCG), and leboeuf, Christophe
Subjects: RISK, Dèficit de ferro, IMPACT, Heart diseases, PHASE, iron deficiency, General Medicine, THERAPY, ferric carboxymaltose, EXERCISE CAPACITY, PREVALENCE, chronic heart failure, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Malalties del cor, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, QUALITY-OF-LIFE, Iron deficiency diseases, HEALTH, guidelines, ANEMIA
Abstract: International audience; Iron deficiency (ID) is a comorbid condition frequently seen in patients with heart failure (HF). Iron has an important role in the transport of oxygen, and is also essential for skeletal and cardiac muscle, which depend on iron for oxygen storage and cellular energy production. Thus, ID per se, even without anaemia, can be harmful. In patients with HF, ID is associated with a poorer quality of life (QoL) and exercise capacity, and a higher risk of hospitalisations and mortality, even in the absence of anaemia. Despite its negative clinical consequences, ID remains under-recognised. However, it is easily diagnosed and managed, and the recently revised 2021 European Society of Cardiology (ESC) guidelines on HF provide specific recommendations for its diagnosis and treatment. Prospective randomised controlled trials in patients with symptomatic HF with reduced ejection fraction (HFrEF) show that correction of ID using intravenous iron (principally ferric carboxymaltose [FCM]) provides improvements in symptoms of HF, exercise capacity and QoL, and a recent trial demonstrated that FCM therapy following hospitalisation due to acute decompensated HF reduced the risk of subsequent HF hospitalisations. This review provides a summary of the epidemiology and pathophysiology of ID in HFrEF, and practical guidance on screening, diagnosing, and treating ID.
Published: 2022

9. Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol

Author: Jane Lise Samuel, Evelyne Polidano, Martin Nicol, Alain Cohen-Solal, Feriel Azibani, Jean-Marie Launay, Malha Sadoune, Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and leboeuf, Christophe
Subjects: Male, Cardiac function curve, lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.medical_specialty, Necrosis, Cardiac fibrosis, 030204 cardiovascular system & hematology, Ventricular Function, Left, Mice, 03 medical and health sciences, 0302 clinical medicine, Atrophy, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Original Research Articles, Internal medicine, medicine, Animals, Original Research Article, 030212 general & internal medicine, Metoprolol, Cardiotoxicity, Ejection fraction, business.industry, Stroke Volume, Cardiac atrophy, Trastuzumab, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Mice, Inbred C57BL, Endocrinology, lcsh:RC666-701, Doxorubicin, Heart failure, medicine.symptom, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: International audience; Aims Our objectives were to validate a murine model of chronic cardiotoxicity induced by Doxorubicin (Dox) and Trastuzumab (Trast) and to test the potential cardio-protective effect of metoprolol. Methods and results Male C57Bl6 mice were intraperitoneally injected during 2 weeks with Dox (24 mg/kg) or saline, and then with Trast (10 mg/kg) or saline for two more weeks. Half of the mice received metoprolol (100 mg/kg). Cardiotoxicity was defined by a decline in left ventricular ejection fraction (LVEF) ≥ 10 points. At Day 42, Dox + Trast-treated mice exhibited a 13-points decline in LVEF (74 ± 2.6% vs. 87 ± 0.8% for control mice, P < 0.001) and a severe cardiac atrophy (heart weight: 105 ± 2.7 mg vs. 119 ± 3.9 mg for control mice, P < 0.01). This cardiac atrophy resulted from an excess of cardiac necrosis (assessed by plasma cardiac troponin I level: 3.2 ± 0.4 ng/L vs. 1.3 ± 0.06 ng/L for control mice, P < 0.01), an increase in apoptosis (caspase 3 activity showing a six-fold increase for Dox + Trast-treated mice vs. controls, P < 0.001), and cardiomyocyte atrophy (myocyte size: 0.67 ± 0.08 μm 2 vs. 1.36 ± 0.10 μm 2 for control mice, P < 0.001). In addition, Dox + Trast-treated mice were shown to have an increased cardiac oxidative stress (164 ± 14 dihydroethidine-marked nuclei per area vs. 56 ± 9.5 for control mice, P < 0.01) and increased cardiac fibrosis (the semi-quantitative fibrosis score was threefold higher for Dox + Trast-treated mice as compared with controls, P < 0.01). Metoprolol was not able to prevent either the decrease in LVEF or the severe cardiac atrophy, the cardiac necrosis, and the cardiac remodelling induced by chemotherapies. Conclusion A murine model of chronic cardiotoxicity induced by Dox and Trast was characterized by a decrease in cardiac function, a cardiac apoptosis and necrosis leading to cardiomyocyte atrophy. Metoprolol did not prevent this cardiotoxicity.
Published: 2021

10. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure

Author: Stefano Savonitto, D Soon, V Tseluyko, J Heymeriks, L Petrescu, Fabio T. M. Costa, P Garcia Pacho, G Chapidze, Michael Motro, M Diez, A Prado, Piotr Ponikowski, Sanjib Kumar Sharma, DL Serban, A. Salvioni, S del Prado, Giuseppe Boriani, Stephan von Haehling, HG Cestari, PR Nierop, LC Iosipescu, Hans Kragten, Má Hominal, Bridget-Anne Kirwan, Andre Keren, D Horvat, J Thierer, D Sim, Rabih R. Azar, Peter van der Meer, G Stanciulescu, F Cosmi, Sy Loh, Jarosław Drożdż, David Sim, K Paposhvili, M Berli, Alain Cohen-Solal, Stefan D. Anker, Arnaout, ML Parody, GO Zapata, T Ben-Gal, J Schaap, Bas L.J.H. Kietselaer, O Raed, G Kiwan, Marco Metra, Shaul Atar, Udo Michael Göhring, Edoardo Gronda, A Ružić, C Beltrano, Dpw Beelen, Davor Milicic, R Ray, JM Weinstein, FI Ga Bosa Ojeda, Y-K Wong, Dalton Bertolim Précoma, Javed Butler, JR Gonzalez Juanatey, V Chumburidze, Gerasimos Filippatos, V Witzling, Y Malynovsky, I Kraiz, A Samodol, J Trevelyan, L Nigro Maia, M Stanislavchuk, Gilmar Reis, I Khintibidze, D Zdrenghea, Beata Wożakowska-Kapłon, BD Molina, C Abdallah, Ham van Kesteren, Tim Friede, Marcin Gruchała, Majdi Halabi, Ewa A. Jankowska, P Van Bergen, Constantin Militaru, O Koval, DA Darabantiu, A Kormann, J Szachniewicz, Maria Dorobantu, M van de Wetering, R Nijmeijer, H Hamdan, Stefano Ghio, Henry J. Dargie, G Azize, Nicolas Danchin, S Chaaban, S Gerward, P Pimentel Filho, M Uguccioni, K Abdelbaki, N Vita, J.F.K. Saraiva, D Almeida, Michael Shochat, M Ohlsson, R Van de Wal, V Zolotaikina, W Kinany, A Tycińska, A Hershson, T Shaburishvili, Vincent Fabien, FR dos Santos, Alfredo Bardají, Rgej Groutars, M Flugelman, J Bono, M Udovicic, M Artuković, K Šutalo, J Drozdz, TJ Yeo, F Ferre Pacora, Z Lominadze, M Emans, S Pettit, HA Luquez, P Terrosu, Marcus Ohlsson, M Gąsior, S Tušek, Enrico Passamonti, Nyy Al-Windy, P Midi, DA Pascual Figal, P van der Meer, V Zvi, Wilco Tanis, Felipe Martinez, RR Borelli, Diana A. Gorog, O Parhomenko, Klaus H Jensen, M Meijs, J Nessler, M Piepoli, DM Toader, Jose C. Nicolau, A Glenny, José Luis Zamorano, L Tilling, T McDonagh, K Pesek, H Fernandez, Davor Miličić, Domingo A. Pascual-Figal, Theresa McDonagh, G Khabeishvili, Josep Comin-Colet, Israel Gotsman, S Rassi, M Dorobantu, E Straburzyńska-Migaj, L Fattore, L Rudenko, D Crisu, S.S. Kabbani, M Gomez Bueno, Basil S. Lewis, S Goland, Y Arbel, M Bronisz, I Vakaliuk, A Fucili, A Mortara, R Zukermann, N Emukhvari, B Hassouna, K Mizia-Stec, F Turrini, R Szelemej, A Rodica Dan, L Lobo Marquez, Hadi Skouri, A Kabir, Frank Ruschitzka, R García Durán, R Gil, Michael Shechter, P Westendorp, Piergiuseppe Agostoni, A Fernandez, Oscar Pereira Dutra, P Ameri, Wolfram Doehner, JG Smith, Irakli Khintibidze, Luciano Moreira Baracioli, J Šikić, Stuart Pocock, Olivier C. Manintveld, MC Tomescu, M Di Biase, Luiz Carlos Bodanese, E Mirek-Bryniarska, Alexander Parkhomenko, Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Cardiology, leboeuf, Christophe, Wrocław Medical University, London School of Hygiene and Tropical Medicine (LSHTM), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], King's College Hospital (KCH), Universitatea din Bucuresti (UB), University of Lódź, Vifor Pharma Ltd [Glattbrugg, Switzerland], National and Kapodistrian University of Athens (NKUA), Hadassah Hebrew University Medical Center [Jerusalem], Tbilisi State University, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Prague University of Economics and Business, Università degli Studi di Brescia = University of Brescia (UniBs), University of Zagreb, Universidade de São Paulo = University of São Paulo (USP), Skane University Hospital [Malmo], Lund University [Lund], National Scientific Center 'M.D. Strazhesko Institute of Cardiology' [Kyiv, Ukraine] (NSC/MDSIC), Universidad de Murcia, University hospital of Zurich [Zurich], National Heart Centre Singapore (NHCS), Saint Joseph Medical Center [Beirut], University Medical Center Groningen [Groningen] (UMCG), Clinical Cardiovascular Research Institute [Haifa, Israel] (2CRI), Bellvitge University Hospital [Barcelona, Spain], University Medical Center Göttingen (UMG), Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Charité Campus Virchow-Klinikum (CVK), University of Glasgow, Tel Aviv University (TAU), University of Southern Mississippi (USM), Socar Research S.A. [Nyon, Switzerland] (SR), and AFFIRM-AHF investigators: G Azize, A Fernandez, G O Zapata, P Garcia Pacho, A Glenny, F Ferre Pacora, M L Parody, J Bono, C Beltrano, A Hershson, N Vita, H A Luquez, H G Cestari, H Fernandez, A Prado, M Berli, R García Durán, J Thierer, M Diez, L Lobo Marquez, R R Borelli, M Á Hominal, M Metra, P Ameri, P Agostoni, A Salvioni, L Fattore, E Gronda, S Ghio, F Turrini, M Uguccioni, M Di Biase, M Piepoli, S Savonitto, A Mortara, P Terrosu, A Fucili, G Boriani, P Midi, E Passamonti, F Cosmi, P van der Meer, P Van Bergen, M van de Wetering, Nyy Al-Windy, W Tanis, M Meijs, Rgej Groutars, Hks The, B Kietselaer, Ham van Kesteren, Dpw Beelen, J Heymeriks, R Van de Wal, J Schaap, M Emans, P Westendorp, P R Nierop, R Nijmeijer, O C Manintveld, M Dorobantu, D A Darabantiu, D Zdrenghea, D M Toader, L Petrescu, C Militaru, D Crisu, M C Tomescu, G Stanciulescu, A Rodica Dan, L C Iosipescu, D L Serban, J Drozdz, J Szachniewicz, M Bronisz, A Tycińska, B Wozakowska-Kaplon, E Mirek-Bryniarska, M Gruchała, J Nessler, E Straburzyńska-Migaj, K Mizia-Stec, R Szelemej, R Gil, M Gąsior, I Gotsman, M Halabi, M Shochat, M Shechter, V Witzling, R Zukermann, Y Arbel, M Flugelman, T Ben-Gal, V Zvi, W Kinany, J M Weinstein, S Atar, S Goland, D Milicic, D Horvat, S Tušek, M Udovicic, K Šutalo, A Samodol, K Pesek, M Artuković, A Ružić, J Šikić, T McDonagh, J Trevelyan, Y-K Wong, D Gorog, R Ray, S Pettit, S Sharma, A Kabir, H Hamdan, L Tilling, L Baracioli, L Nigro Maia, O Dutra, G Reis, P Pimentel Filho, J F Saraiva, A Kormann, F R Dos Santos, L Bodanese, D Almeida, D Precoma, S Rassi, F Costa, S Kabbani, K Abdelbaki, C Abdallah, M S Arnaout, R Azar, S Chaaban, O Raed, G Kiwan, B Hassouna, A Bardaji, J Zamorano, S Del Prado, J R Gonzalez Juanatey, F I Ga Bosa Ojeda, M Gomez Bueno, B D Molina, D A Pascual Figal, D Sim, T J Yeo, S Y Loh, D Soon, M Ohlsson, J G Smith, S Gerward, I Khintibidze, Z Lominadze, G Chapidze, N Emukhvari, G Khabeishvili, V Chumburidze, K Paposhvili, T Shaburishvili, G Khabeishvili, O Parhomenko, I Kraiz, O Koval, V Zolotaikina, Y Malynovsky, I Vakaliuk, L Rudenko, V Tseluyko, M Stanislavchuk.
Subjects: Male, medicine.medical_specialty, Anemia, 030204 cardiovascular system & hematology, Rate ratio, Placebo, Ferric Compounds, Ventricular Function, Left, law.invention, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Double-Blind Method, Randomized controlled trial, law, Internal medicine, medicine, Humans, 030212 general & internal medicine, Maltose, Adverse effect, TOLVAPTAN, Aged, Aged, 80 and over, Heart Failure, RISK, Ejection fraction, Anemia, Iron-Deficiency, business.industry, MORTALITY, Hazard ratio, DEATH, General Medicine, Middle Aged, medicine.disease, Patient Discharge, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Hospitalization, Treatment Outcome, Heart failure, Administration, Intravenous, Female, HOSPITALIZATIONS, business
Abstract: Background: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. Methods: AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin
Published: 2020

11. Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology

Author: Anna Wozniak, Ewa Piotrowicz, Andrew J.S. Coats, Ekaterini Lambrinou, Tiny Jaarsma, Barnabas Gellen, Leonie Klompstra, Martha Kyriakou, Maria Simonenko, Maurizio Volterrani, Massimo F Piepoli, Alain Cohen-Solal, Justien Cornelis, Klaus K. Witte, Emeline M. Van Craenenbroeck, David Niederseer, Francesco Orso, Elena Marques-Sule, Linköping University (LIU), Cyprus University of Technology, Limassol General Hospital, Nicosia General Hospital, Piacenza Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS San Raffaele Pisana), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Antwerp (UA), Belgian Health Care Knowledge Centre (KCE), Polyclinique de Poitiers - ELSAN (2PE), Universitat de València (UV), Universität Zürich [Zürich] = University of Zurich (UZH), University hospital of Zurich [Zurich], Azienda Ospedaliero-Universitaria Careggi [Firenze] (AOUC), National Institute of Cardiology [Warsaw, Poland] (NIC), Antwerp University Hospital [Edegem] (UZA), Ministry of Health of the Russian Federation (MHRF), University of Leeds, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust [Doncaster, UK] (DBTH), IRCCS Ospedale San Raffaele [Milan, Italy], University Medical Center [Utrecht], leboeuf, Christophe, University of Zurich, and Klompstra, Leonie
Subjects: medicine.medical_specialty, Cardiology, Physical activity, 610 Medicine & health, Heart failure, Fitness Trackers, 030204 cardiovascular system & hematology, Medical and Health Sciences, 2705 Cardiology and Cardiovascular Medicine, Exercise Capacity, 03 medical and health sciences, 0302 clinical medicine, Physical medicine and rehabilitation, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, medicine, Humans, Cardiac and Cardiovascular Systems, In patient, Exercise physiology, Association (psychology), Set (psychology), Exercise, Monitoring, Physiologic, Heart Failure, Kardiologi, business.industry, Activity monitor, Motion sensor, Accelerometer, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 10209 Clinic for Cardiology, Position paper, Position Paper, Human medicine, Clinical Medicine, Cardiology and Cardiovascular Medicine, Raw data, business
Abstract: The aims of this paper were to provide an overview of available activity monitors used in research in patients with heart failure and to identify the key criteria in the selection of the most appropriate activity monitor for collecting, reporting, and analysing physical activity in heart failure research. This study was conducted in three parts. First, the literature was systematically reviewed to identify physical activity concepts and activity monitors used in heart failure research. Second, an additional scoping literature search for validation of these activity monitors was conducted. Third, the most appropriate criteria in the selection of activity monitors were identified. Nine activity monitors were evaluated in terms of size, weight, placement, costs, data storage, water resistance, outcomes and validation, and cut-off points for physical activity intensity levels were discussed. The choice of a monitor should depend on the research aims, study population and design regarding physical activity. If the aim is to motivate patients to be active or set goals, a less rigorously tested tool can be considered. On the other hand, if the aim is to measure physical activity and its changes over time or following treatment adjustment, it is important to choose a valid activity monitor with a storage and battery longevity of at least one week. The device should provide raw data and valid cut-off points should be chosen for analysing physical activity intensity levels. Other considerations in choosing an activity monitor should include data storage location and ownership and the upfront costs of the device. Funding Agencies|European Society of Cardiology Funding Source: Medline
Published: 2020

12. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis

Author: Damien Logeart, Stephanie Harel, Alessandro Carecci, Mathilde Baudet, Bertrand Arnulf, Remi Neviere, Michele Emdin, Bruno Royer, Giuseppe Vergaro, Jocelyn Inamo, Olivier Lairez, Alain Cohen-Solal, Thibaud Damy, Astrid Montfort, Antoine Deney, Martin Nicol, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Fondazione Toscana Gabriele Monasterio, École supérieure Sainte-Anne de Pise, CHU de la Martinique [Fort de France], CHU Henri Mondor, Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hopital Saint-Louis [AP-HP] (AP-HP), Université Paris Cité (UPCité), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and leboeuf, Christophe
Subjects: medicine.medical_specialty, medicine.drug_class, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Troponin T, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Interquartile range, Internal medicine, Natriuretic Peptide, Brain, Amyloidosis, Cardiopulmonary exercise test, Circulatory power, Peak oxygen consumption, Prognosis, medicine, Natriuretic peptide, Humans, Aged, Heart Failure, business.industry, Hazard ratio, Middle Aged, medicine.disease, Peptide Fragments, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Blood pressure, Cardiac amyloidosis, Heart failure, Circulatory system, Exercise Test, Cardiology, Cardiology and Cardiovascular Medicine, business, Biomarkers, Respiratory minute volume
Abstract: International audience; Aims: In amyloid patients, cardiac involvement dramatically worsens functional capacity and prognosis. We sought to study how the cardiopulmonary exercise test (CPET) could help in functional assessment and risk stratification of patients with cardiac amyloidosis (CA).Methods and results: We carried out a multicentre study including patients with light chain (AL) or transthyretin (TTR) CA. All patients underwent exhaustive examination including CPET and follow-up. The primary prognostic endpoint was the occurrence of death or heart failure hospitalization. Overall, 150 patients were included (91 AL and 59 TTR CA). Median age, systolic blood pressure, N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac troponin T were 70 (64-78) years, 121 [interquartile range (IQR) 109-139] mmHg, 2806 (IQR 1218-4638) ng/L and 64 (IQR 33-120) ng/L, respectively. New York Heart Association classes were I-II in 64%. Median peak oxygen consumption (VO2 ) and circulatory power were low at 13.0 (10.0-16.9) mL/kg/min and 1730 (1318-2614) mmHg/mL/min, respectively. The minute ventilation/carbon dioxide production slope was increased to 37 (IQR 33-45). A total of 77 patients (51%) had chronotropic insufficiency. After a median follow-up of 20 months, there were 37 deaths and 44 heart failure hospitalizations. At multivariate Cox analysis, peak VO2 ≤13 mL/kg/min [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.6-4.8], circulatory power ≤1730 mmHg/mL/min (HR 2.4, 95% CI 1.2-4.6) and NT-proBNP ≥1800 ng/L (HR 2.2, 95% CI 1.1-4.3) were found to be associated with the primary outcome. No events occurred in patients with both peak VO2 >13 mL/kg/min and NT-proBNP
Published: 2020

13. Mega-trials in heart failure

Author: Peter S. Pang, Barry H. Greenberg, Alexandre Mebazaa, Marco Metra, Koji Takagi, Christopher L. Edwards, John R. Teerlink, Aldo P. Maggioni, Olav W. Nielsen, Gerasimos Filippatos, Piotr Ponikowski, Etienne Gayat, Stefanie Senger, Gad Cotter, Ovidiu Chioncel, Adriaan A. Voors, Alain Cohen-Solal, Georg Ertl, Beth A. Davison, Gary G. Koch, Antoine Kimmoun, Naoki Sato, Cardiovascular Centre (CVC), leboeuf, Christophe, Momentum Research Inc. [Durham, NC, USA] (MRI), Service d'Anesthésie-Réanimation [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), Università degli Studi di Brescia = University of Brescia (UniBs), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], University Medical Center Groningen [Groningen] (UMCG), University of Copenhagen = Københavns Universitet (UCPH), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Indiana University - Purdue University Indianapolis (IUPUI), Indiana University System, University of California [San Diego] (UC San Diego), University of California (UC), Associazione Nazionale Medici Cardiologi Ospedalieri [Firenze] (ANMCO), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Würzburg = Universität Würzburg, Ludwig-Maximilians University [Munich] (LMU), Nippon Medical School Musashi Kosugi Hospital [Kawasaki, Japan] (NMSMKH), Nippon Medical School [Tokyo, Japon], University of California [San Francisco] (UC San Francisco), Veterans Affairs Medical Center, San Francisco, California, National and Kapodistrian University of Athens (NKUA), Wrocław Medical University, College of Engineering, Mathematics and Physical Sciences [Exeter] (EMPS), and University of Exeter
Subjects: medicine.medical_specialty, CLINICAL-OUTCOMES, 030204 cardiovascular system & hematology, Placebo, Article, PATIENT CHARACTERISTICS, law.invention, 03 medical and health sciences, Ventricular Dysfunction, Left, DOUBLE-BLIND, 0302 clinical medicine, VENTRICULAR SYSTOLIC FUNCTION, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Randomized controlled trial, RECEPTOR ANTAGONIST ROLOFYLLINE, law, Internal medicine, Medicine, Humans, Registries, CONVERTING-ENZYME INHIBITORS, Heart Failure, Ejection fraction, business.industry, Acute heart failure, Chronic heart failure, Meta-analysis, MORTALITY, Stroke Volume, Trial Phase, medicine.disease, Prognosis, RANDOMIZED-TRIAL, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Clinical trial, PRESERVED EJECTION FRACTION, Sample size determination, Heart failure, Chronic Disease, Cardiology, QUALITY-OF-CARE, Cardiology and Cardiovascular Medicine, business
Abstract: International audience; Aims: Over the last 30 years, many medicine development programmes in acute and chronic heart failure (HF) with preserved ejection fraction (HFpEF) have failed, in contrast to those in HF with reduced ejection fraction (HFrEF). We explore how the neutral results in larger HF trials may be attributable to chance and/or the dilution of statistical power.Methods and results: Using simulations, we examined the probability that a positive finding in a Phase 2 trial would result in the study of a truly effective medicine in a Phase 3 trial. We assessed the similarity of clinical trial and registry patient populations. We conducted a meta-analysis of paired Phase 2 and 3 trials in HFrEF and acute HF examining the associations of trial phase and size with placebo event rates and treatment effects for HF events and death. We estimated loss in trial power attributable to dilution with increasing trial size. Appropriately powered Phase 3 trials should have yielded ∼35% positive results. Patient populations in Phase 3 trials are similar to those in Phase 2 trials but both differ substantially from the populations of 'real-life' registries. We observed decreasing placebo event rates and smaller treatment effects with increasing trial size, especially for HF events (and less so for mortality). This was more pronounced in trials in acute HF patients.Conclusions: The selection of more positive Phase 2 trials for further development does not explain the failure of HFpEF and acute HF medicine development. Increasing sample size may lead to reduced event rates and smaller treatment effects, resulting in a high rate of neutral Phase 3 trials.
Published: 2020

14. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

Author: Abdul Al-Hesayen, Michel D'Astous, Sheri L. Koshman, Karen Harkness, Lisa Mielniczuk, Heather J. Ross, Marie-Hélène Leblanc, David Z.I. Cherney, Elizabeth Swiggum, Adrian F. Hernandez, Haissam Haddad, Simon Kouz, Shelley Zieroth, Eileen O'Meara, Sabe De, Gordon W. Moe, Robert S. McKelvie, Estrellita Estrella-Holder, Nowell M. Fine, Nadia Giannetti, Frederick A. Masoudi, Michael McDonald, Gideon Cohen, Sylvain Matteau, Sean A. Virani, Olivier Desplantie, Howard Abrams, Margot K. Davis, Diego H. Delgado, Alain Cohen-Solal, Jonathan G. Howlett, Subodh Verma, Anique Ducharme, Anita W. Asgar, Adam Grzeslo, Douglas S. Lee, Lee A. Green, Mustafa Toma, Marie-Claude Parent, Justin A. Ezekowitz, Michael Chan, Serge Lepage, Bruce Sussex, George A. Heckman, Miroslaw Rajda, Montreal Heart Institute - Institut de Cardiologie de Montréal, University of Toronto, University of Alberta, McGill University Health Center [Montreal] (MUHC), McMaster University [Hamilton, Ontario], University of Waterloo [Waterloo], University of Calgary, Université de Sherbrooke (UdeS), University of Ottawa [Ottawa], St. Michael's Hospital, University of British Columbia (UBC), University of Manitoba [Winnipeg], University of Western Ontario (UWO), St. Michael’s Hopsital [Toronto, ON, Canada], Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Dr. Georges-L.-Dumont University Hospital Centre (CHUDGLD), Royal Jubilee Hospital [Victoria, BC, Canada] (RJH), St. Boniface Hospital Albrechtsen Research Centre [Winnipeg], University of Saskatchewan [Saskatoon] (U of S), Hamilton Health Sciences, Duke Clinical Research Institute (DCRI - DURHAM), Duke University [Durham], Centre Hospitalier Régional de Lanaudiere [Joliette, QC, Canada] (CHRDL), Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Université Laval [Québec] (ULaval), University of Colorado Anschutz [Aurora], Western University [London, ON, Canada], QEII Health Sciences Centre [Halifax, NS, Canada] (HSC), Memorial University of Newfoundland = Université Memorial de Terre-Neuve [St. John's, Canada] (MUN), and leboeuf, Christophe
Subjects: Tafamidis, medicine.medical_specialty, Heart Diseases, 030204 cardiovascular system & hematology, Severity of Illness Index, Sacubitril, Angiotensin Receptor Antagonists, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Humans, 030212 general & internal medicine, Sodium-Glucose Transporter 2 Inhibitors, Randomized Controlled Trials as Topic, Heart Failure, Benzoxazoles, Ejection fraction, business.industry, Amyloidosis, Mitral Valve Insufficiency, Stroke Volume, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Clinical trial, Valsartan, Cardiac amyloidosis, chemistry, Heart failure, Cardiology, Neprilysin, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: International audience; In this update, we focus on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provide recommendations and practical tips regarding the management of candidates for the following HF therapies: (1) transcatheter mitral valve repair in HF with reduced ejection fraction; (2) a novel treatment for transthyretin amyloidosis or transthyretin cardiac amyloidosis; (3) angiotensin receptor-neprilysin inhibition in patients with HF and preserved ejection fraction (HFpEF); and (4) sodium glucose cotransport inhibitors for the prevention and treatment of HF in patients with and without type 2 diabetes. We emphasize the roles of optimal guideline-directed medical therapy and of multidisciplinary teams when considering transcatheter mitral valve repair, to ensure excellent evaluation and care of those patients. In the presence of suggestive clinical indices, health care providers should consider the possibility of cardiac amyloidosis and proceed with proper investigation. Tafamidis is the first agent shown in a prospective study to alter outcomes in patients with transthyretin cardiac amyloidosis. Patient subgroups with HFpEF might benefit from use of sacubitril/valsartan, however, further data are needed to clarify the effect of this therapy in patients with HFpEF. Sodium glucose cotransport inhibitors reduce the risk of incident HF, HF-related hospitalizations, and cardiovascular death in patients with type 2 diabetes and cardiovascular disease. A large clinical trial recently showed that dapagliflozin provides significant outcome benefits in well treated patients with HF with reduced ejection fraction (left ventricular ejection fraction ≤ 40%), with or without type 2 diabetes.
Published: 2020

15. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Author: Alexandre Mebazaa, Beth Davison, Ovidiu Chioncel, Alain Cohen-Solal, Rafael Diaz, Gerasimos Filippatos, Marco Metra, Piotr Ponikowski, Karen Sliwa, Adriaan A Voors, Christopher Edwards, Maria Novosadova, Koji Takagi, Albertino Damasceno, Hadiza Saidu, Etienne Gayat, Peter S Pang, Jelena Celutkiene, Gad Cotter, Cardiovascular Centre (CVC), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand-Widal, Momentum Research Inc. [Durham, NC, USA] (MRI), Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu' [Bucharest, Romania], Instituto Cardiovascular de Rosario [Argentina] (ICR), National and Kapodistrian University of Athens (NKUA), University of Athens Medical School [Athens], Università degli Studi di Brescia = University of Brescia (UniBs), University of Wrocław [Poland] (UWr), University of Cape Town, University Medical Center Groningen [Groningen] (UMCG), Eduardo Mondlane University, Bayero University Kano (BUK), Indiana University School of Medicine, Indiana University System, Vilnius University [Vilnius], and leboeuf, Christophe
Subjects: Male, Heart Failure, Treatment Outcome, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Quality of Life, Humans, Female, Stroke Volume, General Medicine, Middle Aged, Ventricular Function, Left, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Mineralocorticoid Receptor Antagonists
Abstract: Background: There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.Methods: In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18–85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete.Findings: Between May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (Interpretation: An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.Funding: Roche Diagnostics.
Published: 2022

16. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF

Author: Gregory D. Lewis, Kieran F. Docherty, Adriaan A. Voors, Alain Cohen-Solal, Marco Metra, David J. Whellan, Justin A. Ezekowitz, Piotr Ponikowski, Michael Böhm, John R. Teerlink, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Lisa Meng, G. Michael Felker, Cardiovascular Centre (CVC), Massachusetts General Hospital [Boston], University of Glasgow, University Medical Center Groningen [Groningen] (UMCG), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Università degli Studi di Brescia = University of Brescia (UniBs), Jefferson (Philadelphia University + Thomas Jefferson University), University of Alberta, University of Wrocław [Poland] (UWr), Saarland University [Saarbrücken], University of California [San Francisco] (UC San Francisco), University of California (UC), Veterans Affairs Medical Center, San Francisco, California, Cytokinetics Inc. [South San Francisco, CA, USA] (CI), Duke University [Durham], and leboeuf, Christophe
Subjects: LONG-TERM, Left, Ventricular Dysfunction, Left, DOUBLE-BLIND, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, QUALITY-OF-LIFE, Ventricular Dysfunction, Humans, Multicenter Studies as Topic, OMECAMTIV MECARBIL, quality of life, Heart Failure, CARDIAC-RESYNCHRONIZATION THERAPY, exercise tolerance, heart failure, oxygen consumption, Exercise Tolerance, Myocardial Contraction, Oxygen, Stroke Volume, VENTRICULAR SYSTOLIC DYSFUNCTION, CONTRACTILITY MODULATION, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, PHYSICAL-ACTIVITY, PRESERVED EJECTION FRACTION, SKELETAL-MUSCLE, Cardiology and Cardiovascular Medicine
Abstract: Heart failure with reduced ejection fraction (HFrEF) is a highly morbid condition for which exercise intolerance is a major manifestation. However, methods to assess exercise capacity in HFrEF vary widely in clinical practice and in trials. We describe advances in exercise capacity assessment in HFrEF and a comparative analysis of how various therapies available for HFrEF impact exercise capacity. Current guideline-directed medical therapy has indirect effects on cardiac performance with minimal impact on measured functional capacity. Omecamtiv mecarbil is a novel selective cardiac myosin activator that directly increases cardiac contractility and in a phase 3 cardiovascular outcomes study significantly reduced the primary composite end point of time to first heart failure event or cardiovascular death in patients with HFrEF. The objective of the METEORIC-HF trial (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure) is to assess the effect of omecamtiv mecarbil versus placebo on multiple components of functional capacity in HFrEF. The primary end point is to test the effect of omecamtiv mecarbil compared with placebo on peak oxygen uptake as measured by cardiopulmonary exercise testing after 20 weeks of treatment. METEORIC-HF will provide state-of-the-art assessment of functional capacity by measuring ventilatory efficiency, circulatory power, ventilatory anaerobic threshold, oxygen uptake recovery kinetics, daily activity, and quality-of-life assessment. Thus, the METEORIC-HF trial will evaluate the potential impact of increased myocardial contractility with omecamtiv mecarbil on multiple important measures of functional capacity in ambulatory patients with symptomatic HFrEF. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT03759392.
Published: 2022

17. Recent advances in cardio-oncology

Author: Christoph Maack, Stephan von Haehling, Alexander R. Lyon, Y N Belenkov, Sara Hadzibegovic, Hadi Skouri, Alessia Lena, Petar M. Seferovic, Rudolf A. de Boer, Markus S. Anker, Radek Pudil, Andrew J.S. Coats, Carlo G. Tocchetti, Zaza Iakobishvili, Dimitrios Farmakis, Jutta Bergler-Klein, Alain Cohen-Solal, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Sechenov First Moscow State Medical University, Medizinische Universität Wien = Medical University of Vienna, University Medical Center Groningen [Groningen] (UMCG), University of Cyprus [Nicosia] (UCY), National and Kapodistrian University of Athens (NKUA), Georg-August-University = Georg-August-Universität Göttingen, Tel Aviv University (TAU), University Hospital of Würzburg, University of Hradec Králové, American University of Beirut Faculty of Medicine and Medical Center (AUB), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Naples Federico II = Università degli studi di Napoli Federico II, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS San Raffaele Pisana), University of Belgrade [Belgrade], Royal Brompton Hospital, Imperial College London, leboeuf, Christophe, Anker, M. S., Hadzibegovic, S., Lena, A., Belenkov, Y., Bergler-Klein, J., de Boer, R. A., Farmakis, D., von Haehling, S., Iakobishvili, Z., Maack, C., Pudil, R., Skouri, H., Cohen-Solal, A., Tocchetti, C., Coats, A. J. S., Seferovic, P. M., Lyon, A. R., and Cardiovascular Centre (CVC)
Subjects: IMMUNE CHECKPOINT INHIBITOR, CHRONIC KIDNEY-DISEASE, CARDIOTOXICITY, medicine.medical_specialty, lcsh:Diseases of the circulatory (Cardiovascular) system, Palliative care, medicine.medical_treatment, Cardiology, Heart failure, Disease, 030204 cardiovascular system & hematology, ESC and HFA Paper, ESC and HFA Papers, Targeted therapy, PALLIATIVE CARE, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, BREAST-CANCER SURVIVORS, Neoplasms, medicine, INDEPENDENT PREDICTOR, CO-MORBIDITIES, Humans, 030212 general & internal medicine, Cardio oncology, Intensive care medicine, Cancer, Cardiotoxicity, business.industry, medicine.disease, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, PREVALENCE, Radiation therapy, lcsh:RC666-701, Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology, Position paper, Cardiology and Cardiovascular Medicine, business, ECHOCARDIOGRAPHY, Cardiotoxicity Heart failure Cancer, POSITION PAPER
Abstract: International audience; While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.
Published: 2019

18. Determinants of left atrioventricular coupling index: The Multi-Ethnic Study of Atherosclerosis (MESA)

Author: Theo Pezel, Bharath Ambale Venkatesh, Henrique Doria De Vasconcellos, Yoko Kato, Wendy S. Post, Colin O. Wu, Susan R. Heckbert, David A. Bluemke, Alain Cohen-Solal, Damien Logeart, Patrick Henry, João A.C. Lima, Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Johns Hopkins University (JHU), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), National Heart, Lung, and Blood Institute [Bethesda] (NHLBI), University of Washington [Seattle], University of Wisconsin School of Medicine and Public Health, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and leboeuf, Christophe
Subjects: Male, Cardiac magnetic resonance, Heart Ventricles, Multi-Ethnic Study of Atherosclerosis (MESA), Étude Multi-Ethnique de l’Athérosclérose (MESA), General Medicine, Left ventricle, Middle Aged, Atherosclerosis, Fibrosis, Imagerie par résonance magnétique cardiaque, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Coupling, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Couplage, Left atrium, Oreillette gauche, Diabetes Mellitus, Ethnicity, Humans, Female, Cardiology and Cardiovascular Medicine, Ventricule gauche, Biomarkers, Aged
Abstract: Background Recent studies have described a novel left atrioventricular coupling index (LACI), which had a better prognostic value than individual left atrial (LA) or left ventricular (LV) parameters measured separately to predict cardiovascular events. Purpose To identify the determinants of the LACI and its 10-year annual change (ΔLACI), measured by cardiovascular magnetic resonance (CMR), and to better understand the parameters governing this left atrioventricular coupling. Methods In the Multi-Ethnic Study of Atherosclerosis (MESA), 2,112 study participants, free of cardiovascular disease at baseline, had LACI assessed by CMR imaging at baseline (LACIBaseline, 2000–2002) and 10 years later (2010–2012). The LACI was defined as the ratio of LA to LV end-diastolic volumes. Linear regression analyses were performed to identify independent determinants of LACIBaseline or ΔLACI. Results In the 2,112 participants (58.8±9.1 years, 46.6% male), after adjustment for all covariates, age was independently associated with both LACIBaseline (R2=0.10, slope=0.16) and ΔLACI (R2=0.15, slope=0.008, both p Conclusions Age, sex, ethnicity, diabetes, and BMI were independent determinants of LACI. LACI was independently associated with LV myocardial fibrosis markers and NT-proBNP levels. Funding Acknowledgement Type of funding sources: None.
Published: 2021

19. Left Atrioventricular Coupling Index to Predict Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis

Author: Susan R. Heckbert, Théo Pezel, Henrique Doria de Vasconcellos, Wendy S. Post, Patrick Henry, David A. Bluemke, Colin O. Wu, Joao A.C. Lima, Yoko Kato, Alain Cohen-Solal, Bharath Ambale Venkatesh, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Johns Hopkins University School of Medicine [Baltimore], University of Washington [Seattle], National Heart, Lung, and Blood Institute [Bethesda] (NHLBI), University of Wisconsin School of Medicine and Public Health, and leboeuf, Christophe
Subjects: medicine.medical_specialty, left ventricle, Population, heart failure, multiethnic study of atherosclerosis, Cardiovascular Medicine, left atria, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Left atrial, Internal medicine, multi-ethnic study of atherosclerosis, medicine, Diseases of the circulatory (Cardiovascular) system, Multivariable model, coupling, education, Original Research, education.field_of_study, Framingham Risk Score, medicine.diagnostic_test, business.industry, Incidence (epidemiology), cardiac magnetic resonance image, Mean age, Magnetic resonance imaging, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, RC666-701, Heart failure, Cardiology, prognosis, Cardiology and Cardiovascular Medicine, business
Abstract: Background: Although left atrial (LA) and left ventricular (LV) structural and functional parameters have independent prognostic value as predictors of heart failure (HF), the close physiological relationship between the LA and LV suggest that the assessment of LA/LV coupling could better reflect left atrioventricular dysfunction and be a better predictor of HF.Aim: We investigated the prognostic value of a left atrioventricular coupling index (LACI), measured by cardiovascular magnetic resonance (CMR), as well as change in LACI to predict incident HF in the Multi-Ethnic Study of Atherosclerosis (MESA).Materials and Methods: In the MESA, 2,250 study participants, free of clinically recognized HF and cardiovascular disease (CVD) at baseline, had LACI assessed by CMR imaging at baseline (Exam 1, 2000–2002), and 10 years later (Exam 5, 2010–2012). Left atrioventricular coupling index was defined as the ratio of LA to LV end-diastolic volumes. Univariable and multivariable Cox proportional hazard models were used to evaluate the associations of LACI and average annualized change in LACI (ΔLACI) with incident HF after adjustment for traditional MESA-HF risk factors. The incremental risk prediction was calculated using C-statistic, categorical net reclassification index (NRI) and integrative discrimination index (IDI).Results: Among the 2,250 participants (mean age 59.3 ± 9.3 years and 47.6% male participants), 50 incident HF events occurred over 6.8 ± 1.3 years after the second CMR exam. After adjustment, greater LACI and ΔLACI were independently associated with HF (adjusted HR 1.44, 95% CI [1.25–1.66] and adjusted HR 1.55, 95% CI [1.30–1.85], respectively; both p < 0.0001). Adjusted models for LACI showed significant improvement in model discrimination and reclassification compared to currently used HF risk score model for predicting HF incidence (C-statistic: 0.81 vs. 0.77; NRI = 0.411; IDI = 0.043). After adjustment, ΔLACI showed also significant improvement in model discrimination compared to the multivariable model with traditional MESA-HF risk factors for predicting incident HF (C-statistic: 0.82 vs. 0.77; NRI = 0.491; IDI = 0.058).Conclusions: In a multi-ethnic population, atrioventricular coupling (LACI), and coupling change (ΔLACI) are independently associated with incident HF. Both have incremental prognostic value for predicting HF events over traditional HF risk factors.
Published: 2021

20. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: The results of the AFFIRM-AHF study

Author: Marco Metra, Marcus Andreas Ohlsson, Basil S. Lewis, Wolfram Doehner, Peter van der Meer, Irakli Khintibidze, Hans Kragten, Bridget-Anne Kirwan, Jose C. Nicolau, Vincent Fabien, Tim Friede, Nicolas Danchin, Ewa A. Jankowska, Gerasimos Filippatos, Alain Cohen-Solal, Fabio Dorigotti, Hadi Skouri, Davor Miličić, Andre Keren, Alexander Parkhomenko, Jarosław Drożdż, David Sim, Stuart J. Pocock, Michael Motro, Javed Butler, Domingo A. Pascual-Figal, Theresa McDonagh, Henry J. Dargie, Josep Comín-Colet, Maria Dorobantu, Mikhail Kosiborod, Frank Ruschitzka, Stephan von Haehling, Piotr Ponikowski, Stefan D. Anker, Felipe Martinez, Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), leboeuf, Christophe, Wrocław Medical University, Socar Research S.A. [Nyon, Switzerland] (SR), London School of Hygiene and Tropical Medicine (LSHTM), Saint Luke's Mid America Heart Institute, University of Missouri [Kansas City] (UMKC), University of Missouri System, University of Mississippi Medical Center (UMMC), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], King‘s College London, Universitatea din Bucuresti (UB), Medical University of Łódź (MUL), National and Kapodistrian University of Athens (NKUA), Université d'Athènes (UOA), Assuta Hospital in Ramat HaHayal [Tel Aviv-Yafo, Israel] (AHRH), Tbilisi State University, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Prague University of Economics and Business, Università degli Studi di Brescia = University of Brescia (UniBs), Civic Hospital of Brescia, University of Zagreb, Skane University Hospital [Malmo], Lund University [Lund], National Scientific Center 'M.D. Strazhesko Institute of Cardiology' [Kyiv, Ukraine] (NSC/MDSIC), Universidad de Murcia, University hospital of Zurich [Zurich], National Heart Centre Singapore (NHCS), American University of Beirut Faculty of Medicine and Medical Center (AUB), University Medical Center Groningen [Groningen] (UMCG), Rappaport faculty of Medicine, Technion - Israel Institute of Technology [Haifa], L’Hospitalet de Llobregat [Barcelona, Spain], Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), University Medical Center Göttingen (UMG), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), University of Glasgow, Tel Aviv University (TAU), Kfar Saba and Sackler School of Medicine, Vifor Pharma Ltd [Glattbrugg, Switzerland], and University College of London [London] (UCL)
Subjects: medicine.medical_specialty, Randomization, Heart diseases, Iron, Health-related quality of life, Population, Heart failure, 030204 cardiovascular system & hematology, Placebo, law.invention, Malalties del cor, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, law, Clinical Research, Internal medicine, medicine, Humans, Clinical Trials, AcademicSubjects/MED00200, 030212 general & internal medicine, education, education.field_of_study, Ejection fraction, Dèficit de ferro, Anemia, Iron-Deficiency, business.industry, Iron deficiency, Acute heart failure, medicine.disease, Confidence interval, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Dietary Supplements, Intravenous ferric carboxymaltose therapy, Iron deficiency diseases, Randomized clinical trial, Cardiology and Cardiovascular Medicine, business
Abstract: Aims Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. Methods and results The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean ± standard error was 38.7 ± 0.9 (FCM group) and 37.1 ± 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 ± 0.9 and 40.1 ± 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5–5.3, P = 0.018) for OSS and 2.8 (0.3–5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3–5.6, P = 0.028) for OSS and 2.9 (0.2–5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM. Conclusion In iron-deficient patients with HF and left ventricular ejection fraction, Graphical Abstract
Published: 2021

21. Amended STRONG-HF study design

Author: Imad Merai, Koji Takagi, Marco Metra, Hans-Dirk Duengen, Piotr Ponikowski, Albertino Damasceno, Gad Cotter, Karen Sliwa, Ovidiu Chioncel, Eva Goncalvesova, Beth A. Davison, Gerasimos Filippatos, Hadiza Saidu, Mahmoud U Sani, Alexandre Mebazaa, Zaur Shogenov, Alain Cohen Solal, Dmitry Privalov, Adriaan A. Voors, Faouzi Addad, Rafael Diaz, Jelena Celutkiene, Cardiovascular Centre (CVC), Momentum Research Inc. [Durham, NC, USA] (MRI), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Università degli Studi di Brescia = University of Brescia (UniBs), Civic Hospital of Brescia, University of Cape Town, University of Groningen [Groningen], Hôpital Abderrahmen Mami, Vilnius University [Vilnius], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Instituto Cardiovascular de Rosario [Argentina] (ICR), Eduardo Mondlane University, Charité Campus Virchow-Klinikum (CVK), National and Kapodistrian University of Athens (NKUA), Université d'Athènes (UOA), Attikon University Hospital, National Institute of Cardiovascular Diseases [Bratislava, Slovak Republic] (NICD), Moscow City Clinical Hospital [Moscow, Russia] (M2CH), Wrocław Medical University, Bayero University Kano (BUK), Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand-Widal, and leboeuf, Christophe
Subjects: Heart Failure, medicine.medical_specialty, business.industry, MEDLINE, medicine.disease, DIAGNOSIS, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Heart failure, Humans, medicine, ESC GUIDELINES, Cardiology and Cardiovascular Medicine, Intensive care medicine, business
Abstract: International audience; No abstract available
Published: 2021

22. Acute heart failure treatment: a light at the end of the tunnel?

Author: Alain Cohen-Solal, Christopher L. Edwards, Koji Takagi, Gad Cotter, Beth A. Davison, Alexandre Mebazaa, Momentum Research Inc. [Durham, NC, USA] (MRI), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and leboeuf, Christophe
Subjects: Heart Failure, medicine.medical_specialty, business.industry, MEDLINE, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Text mining, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Heart failure, medicine, Humans, Cardiology and Cardiovascular Medicine, Intensive care medicine, business
Abstract: International audience; No abstract available
Published: 2021

23. Right ventricular function and iron deficiency in acute heart failure

Author: Alain Cohen-Solal, Vicent Bodí, Enrique Santas, Juan Sanchis, Ernesto Valero, Gema Miñana, Eduardo Núñez, Gonzalo Núñez, Miguel Lorenzo, Francisco J. Chorro, Rafael de la Espriella, Antoni Bayes-Genis, Julio Núñez, Universitat de València (UV), Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares [Spain] (CIBERCV), Instituto de Salud Carlos III [Madrid] (ISC), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Universitat Autònoma de Barcelona (UAB), Germans Trias i Pujol University Hospital [Badalona, Barcelona, Spain] (GTPUH), and leboeuf, Christophe
Subjects: medicine.medical_specialty, Ventricular Dysfunction, Right, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, Ventricular Function, Left, 03 medical and health sciences, 0302 clinical medicine, Left ventricle ejection fraction, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Interquartile range, Internal medicine, medicine, Humans, 030212 general & internal medicine, Systole, Aged, Aged, 80 and over, Heart Failure, Iron deficiency, Ejection fraction, Anemia, Iron-Deficiency, biology, Transferrin saturation, business.industry, Right ventricle ejection fraction, Stroke Volume, General Medicine, Middle Aged, Prognosis, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Tricuspid annular plane systolic excursion, Ferritin, Blood pressure, Heart failure, Ventricular Function, Right, biology.protein, Cardiology, Female, Cardiology and Cardiovascular Medicine, Heart failure with preserved ejection fraction, business
Abstract: Aims Iron deficiency (ID) is a frequent finding in patients with chronic and acute heart failure (AHF) along the full spectrum of left ventricular ejection fraction (LVEF). Iron deficiency has been related to ventricular systolic dysfunction, but its role in right ventricular function has not been evaluated. We sought to evaluate whether ID identifies patients with greater right ventricular dysfunction in the setting of AHF. Methods and results We prospectively included 903 patients admitted with AHF. Right systolic function was evaluated by tricuspid annular plane systolic excursion (TAPSE) and the ratio TAPSE/pulmonary artery systolic pressure (TAPSE/PASP). Iron deficiency was defined, according to European Society of Cardiology criteria, as serum ferritin Conclusion In AHF, proxies of ID were associated with right ventricular dysfunction. Further studies should confirm these findings and evaluate the pathophysiological facts behind this association.
Published: 2021

24. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

Author: Frederick A. Masoudi, Kim Anderson, Simon Kouz, Douglas S. Lee, Shelley Zieroth, Michel D'Astous, Sean A. Virani, Sabina L.C. Keen, Stephanie Poon, Mustafa Toma, Brian Clarke, Kate Storm, Eileen O'Meara, Elizabeth Swiggum, Abhinav Sharma, Andrew Grant, Sharon A Bray, Gordon W. Moe, Marie-Claude Parent, Nadia Giannetti, George A. Heckman, Michael Chan, Justin A. Ezekowitz, Jodi Heshka, Bruce Sussex, Harriette G.C. Van Spall, Miroslaw Rajda, Sabe De, Amelia Ming Ching Yip, Adam Grzeslo, Jonathan G. Howlett, Lisa Mielniczuk, Serge Lepage, Sheri L. Koshman, Robert S. McKelvie, Michael McDonald, Margot K. Davis, Alain Cohen-Solal, Anique Ducharme, Kyla Siatecki, leboeuf, Christophe, TGH Peter Munk Cardiac Centre [Toronto, ON, Canada] (PMCC), University of British Columbia (UBC), University of Alberta, Montreal Heart Institute - Institut de Cardiologie de Montréal, McGill University Health Center [Montreal] (MUHC), University of Waterloo [Waterloo], University of Calgary, Université de Sherbrooke (UdeS), University of Ottawa [Ottawa], St. Michael's Hospital, University of Manitoba [Winnipeg], Dalhousie University [Halifax], The Pirbright Institute, Biotechnology and Biological Sciences Research Council (BBSRC), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Dr. Georges-L.-Dumont University Hospital Centre (CHUDGLD), Western University [London, ON, Canada], McMaster University [Hamilton, Ontario], Institut de cardiologie de l'Université d'Ottawa [Ottawa, ON, Canada] (ICUO), Centre Hospitalier Régional de Lanaudiere [Joliette, QC, Canada] (CHRDL), University of Colorado Anschutz [Aurora], Sunnybrook Health Sciences Centre, McGill University = Université McGill [Montréal, Canada], and Memorial University of Newfoundland = Université Memorial de Terre-Neuve [St. John's, Canada] (MUN)
Subjects: Canada, medicine.medical_specialty, Angiotensin receptor, Digoxin, medicine.medical_treatment, Myocardial Infarction, Cardiac resynchronization therapy, Context (language use), 030204 cardiovascular system & hematology, Cardiac Resynchronization Therapy, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Heart Rate, Internal medicine, medicine, Humans, 030212 general & internal medicine, Randomized Controlled Trials as Topic, Heart Failure, Ejection fraction, biology, business.industry, Cardiovascular Agents, Standard of Care, Stroke Volume, Angiotensin-converting enzyme, Canadian Cardiovascular Society, medicine.disease, Defibrillators, Implantable, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Hospitalization, Heart failure, biology.protein, Cardiology, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: International audience; In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we provide comprehensive recommendations and practical tips for the pharmacologic management of patients with HF with reduced ejection fraction (HFrEF). Since the 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of HF, substantial new evidence has emerged that has informed the care of these patients. In particular, we focus on the role of novel pharmacologic therapies for HFrEF including angiotensin receptor-neprilysin inhibitors, sinus node inhibitors, sodium glucose transport 2 inhibitors, and soluble guanylate cyclase stimulators in conjunction with other long established HFrEF therapies. Updated recommendations are also provided in the context of the clinical setting for which each of these agents might be prescribed; the potential value of each therapy is reviewed, where relevant, for chronic HF, new onset HF, and for HF hospitalization. We define a new standard of pharmacologic care for HFrEF that incorporates 4 key therapeutic drug classes as standard therapy for most patients: an angiotensin receptor-neprilysin inhibitor (as first-line therapy or after angiotensin converting enzyme inhibitor/angiotensin receptor blocker titration); a β-blocker; a mineralocorticoid receptor antagonist; and a sodium glucose transport 2 inhibitor. Additionally, many patients with HFrEF will have clinical characteristics for which we recommended other key therapies to improve HF outcomes, including sinus node inhibitors, soluble guanylate cyclase stimulators, hydralazine/nitrates in combination, and/or digoxin. Finally, an approach to management that integrates prioritized pharmacologic with nonpharmacologic and invasive therapies after a diagnosis of HFrEF is highlighted.
Published: 2021

25. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

Author: Wilfried Mullens, Dimitrios Farmakis, Tuvia Ben Gal, Gerasimos Filippatos, Tiny Jaarsma, Robin Ray, Ekaterini Lambrinou, Gianluigi Savarese, Carlo G. Tocchetti, Alain Cohen-Solal, Yuri N. Belenkov, Maurizio Volterrani, Stamatis Adamopoulos, Arsen D. Ristić, Brenda Moura, Amina Rakisheva, Arantxa González, Michele Senni, Finn Gustafsson, Antoni Bayes-Genis, Thomas Thum, Ovidiu Chioncel, Marco Metra, Magdy Abdelhamid, Fadi Jouhra, Y M Lopatin, Lars Lund, Giuseppe M.C. Rosano, Sophie Van Linthout, Davor Miličić, Petar M. Seferovic, Piotr Ponikowski, Andrew J.S. Coats, Mitja Lainscak, Massimo F Piepoli, Michael Böhm, Loreena Hill, Stefan D. Anker, Ewa A. Jankowska, Rosano, G, Jankowska, E, Ray, R, Metra, M, Abdelhamid, M, Adamopoulos, S, Anker, S, Bayes-Genis, A, Belenkov, Y, Gal, T, Böhm, M, Chioncel, O, Cohen-Solal, A, Farmakis, D, Filippatos, G, González, A, Gustafsson, F, Hill, L, Jaarsma, T, Jouhra, F, Lainscak, M, Lambrinou, E, Lopatin, Y, Lund, L, Milicic, D, Moura, B, Mullens, W, Piepoli, M, Ponikowski, P, Rakisheva, A, Ristic, A, Savarese, G, Seferovic, P, Senni, M, Thum, T, Tocchetti, C, Van Linthout, S, Volterrani, M, Coats, A, IRCCS San Raffaele [Rome, Italy], Wrocław Medical University, University of London [London], St George’s University Hospitals, Università degli Studi di Brescia = University of Brescia (UniBs), Civic Hospital of Brescia, Cairo University, Onassis Cardiac Surgery Center [Athens] (OCSC), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), Université de Barcelonne, Instituto de Salud Carlos III [Madrid] (ISC), Germans Trias i Pujol University Hospital [Badalona, Barcelona, Spain] (GTPUH), Sechenov First Moscow State Medical University, Tel Aviv University (TAU), Universität des Saarlandes [Saarbrücken], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Cyprus [Nicosia] (UCY), National and Kapodistrian University of Athens (NKUA), Center for Applied Medical Research [Plamplona] (CIMA), Universidad de Navarra [Pamplona] (UNAV), University of Copenhagen = Københavns Universitet (UCPH), Queen's University [Belfast] (QUB), Linköping University (LIU), University of Ljubljana, Cyprus University of Technology, Volgograd State Medical University [Russian Federation] (VSMU), Karolinska University Hospital [Stockholm], University of Zagreb, Universidade do Porto = University of Porto, Hasselt University (UHasselt), Ziekenhuis Oost-Limburg (ZOL), Università degli studi di Parma = University of Parma (UNIPR), Al-Farabi Kazakh National University [Almaty] (KazNU), University of Belgrade [Belgrade], Serbian Academy of Sciences and Arts (SASA), Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Fraunhofer Institute for Toxicology and Experimental Medicine (Fraunhofer ITEM), Fraunhofer (Fraunhofer-Gesellschaft), University of Naples Federico II = Università degli studi di Napoli Federico II, German Center for Cardiovascular Research (DZHK), University of Warwick [Coventry], leboeuf, Christophe, Publica, Rosano, G., Jankowska, E. A., Ray, R., Metra, M., Abdelhamid, M., Adamopoulos, S., Anker, S. D., Bayes-Genis, A., Belenkov, Y., Gal, T. B., Bohm, M., Chioncel, O., Cohen-Solal, A., Farmakis, D., Filippatos, G., Gonzalez, A., Gustafsson, F., Hill, L., Jaarsma, T., Jouhra, F., Lainscak, M., Lambrinou, E., Lopatin, Y., Lund, L. H., Milicic, D., Moura, B., Mullens, W., Piepoli, M. F., Ponikowski, P., Rakisheva, A., Ristic, A., Savarese, G., Seferovic, P., Senni, M., Thum, T., Tocchetti, C. G., Van Linthout, S., Volterrani, M., and Coats, A. J. S.
Subjects: medicine.medical_specialty, COVID-19 Vaccines, medicine.medical_treatment, media_common.quotation_subject, Frail Elderly, Frailty syndrome, Cardiology, Heart failure, Disease, Medical and Health Sciences, SARS‐CoV‐2, [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology, SDG 3 - Good Health and Well-being, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, COVID‐19, Hygiene, medicine, Humans, Intensive care medicine, media_common, Aged, Heart transplantation, HFA position paper, business.industry, SARS-CoV-2, Social distance, Vaccination, COVID-19, Iron Deficiencies, medicine.disease, failure, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Heart Failure, Position paper, Position Paper, Clinical Medicine, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Cardiology and Cardiovascular Medicine, business
Abstract: Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF. This article is protected by copyright. All rights reserved. [Abstract copyright: This article is protected by copyright. All rights reserved.]
Published: 2021

26. New treatments for heart failure and exercise capacity

Author: Florence Beauvais, Alain Cohen-Solal, leboeuf, Christophe, Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Heart Failure, medicine.medical_specialty, Exercise Tolerance, business.industry, MEDLINE, Exercise capacity, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Text mining, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Heart failure, medicine, Humans, Cardiology and Cardiovascular Medicine, Intensive care medicine, business
Abstract: International audience; No abstract available
Published: 2021

27. Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors

Author: Motiejunaite, Justina, Balagny, Pauline, Arnoult, Florence, Mangin, Laurence, Bancal, Catherine, Vidal-Petiot, Emmanuelle, Flamant, Martin, Jondeau, Guillaume, Cohen-Solal, Alain, d'Ortho, Marie-Pia, Frija-Masson, Justine, leboeuf, Christophe, Service de physiologie clinique [Paris], Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cohortes épidémiologiques en population (CONSTANCES), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université Paris Cité (UPCité), Matière et Systèmes Complexes (MSC (UMR_7057)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université Paris Cité (UPCité), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Maladies neurodéveloppementales et neurovasculaires (NeuroDiderot (UMR_S_1141 / U1141)), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
Subjects: [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Abstract: Conflict of interest statementConflict of interest: E. Vidal-Petiot reports personal fees and non-financial support from Servier, outside the submitted work. A. Cohen-Solal has received grants or honoraria from Novartis, Servier, Daiichi Sankyo, Vifor, Menarini and Cardiorentis, outside of the submitted work. J. Frija-Masson reports non-financial support from Vitalaire, Boehringer Ingelheim, Oxyvie and LVL Medical, outside the submitted work. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.; International audience; Inadequate exercise hyperventilation should not be overlooked while exploring the causes of exertional dyspnoea in SARS-CoV-2 survivors https://bit.ly/3AxOiDh
Published: 2021

28. Characterization of non‐response to cardiac resynchronization therapy by post‐procedural computed tomography

Author: Jean Pierre Laissy, Damien Logeart, Théo Pezel, Alain Cohen-Solal, Delphine Mika, Florence Beauvais, Ghassan Moubarak, Patrick Henry, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Signalisation et physiopathologie cardiovasculaire (CARPAT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris Cité (UPCité), Hôpital Ambroise Paré [AP-HP], and leboeuf, Christophe
Subjects: Male, medicine.medical_specialty, medicine.medical_treatment, dyssynchrony, Cardiac resynchronization therapy, Contrast Media, cardiac resynchronization therapy, Computed tomography, Image subtraction, 030204 cardiovascular system & hematology, Lead location, Coronary Angiography, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Humans, 030212 general & internal medicine, Wall motion, Cardiac Resynchronization Therapy Devices, Treatment Failure, Aged, Coronary Vein, coronary veins, medicine.diagnostic_test, business.industry, computed tomography, General Medicine, Middle Aged, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Echocardiography, Subtraction Technique, Cardiology, Radiographic Image Interpretation, Computer-Assisted, Myocardial fibrosis, Female, myocardial fibrosis, Cardiology and Cardiovascular Medicine, Wall thickness, business, Tomography, X-Ray Computed, late iodine enhancement
Abstract: International audience; Introduction: Causes of non-response to cardiac resynchronization therapy (CRT) include mechanical dyssynchrony, myocardial scar, and suboptimal left ventricular (LV) lead location. We aimed to assess the utility of Late Iodine Enhancement Computed Tomography (LIE-CT) with image subtraction in characterizing CRT non-response. Methods: CRT response was defined as a decrease in LV end-systolic volume > 15% at 6 months. LIE-CT was performed after 6 months, and analyzed global and segmental dyssynchrony, myocardial scar, coronary venous anatomy, and position of LV lead relative to scar and segment of latest mechanical contraction. Results: We evaluated 29 patients (age 71 ± 12 years; 72% men) including 18 (62%) responders. All metrics evaluating residual dyssynchrony such as wall motion index and wall thickness index were worse in non-responders. There was no difference in presence and extent of scar between responders and non-responders. However, in non-responders, the LV lead was more often over an akinetic/dyskinetic area (72% vs. 22%, p = .007), a fibrotic area (64% vs. 8%, p = .0007), an area with myocardial thickness < 6 mm (82% vs. 22%, p = .002), and less often concordant with the region of maximal wall thickness (9% vs. 72%, p = .001). Among the 11 non-responders, eight had at least another coronary venous branch visualized by CT, including three (27%) coursing over a potentially interesting myocardial area (free of scar, with normal wall motion, and with a myocardial thickness ≥6 mm). Conclusion: LIE-CT with image subtraction allows a comprehensive characterization of patients after CRT and may provide clues for management of non-responders.
Published: 2020

29. The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey

Author: George A. Heckman, Sean A. Virani, Howard Abrams, Nadia Giannetti, S. Lepage, Eileen O'Meara, Douglas Lee, Marie-Hélène Leblanc, Simon Kouz, Elizabeth Swiggum, Estrellita Estrella-Holder, Heather J. Ross, Adrian F. Hernandez, Frederick A. Masoudi, Sylvain Matteau, Gordon W. Moe, Bruce Sussex, Michel D'Astous, Alain Cohen-Solal, Miroslaw Rajda, Sabe De, Sharon A Bray, Lee A. Green, Sheri L. Koshman, Marie-Claude Parent, Adam Grzeslo, Jonathan G. Howlett, Diego H. Delgado, Secondary Panel, Anique Ducharme, Lisa Mielniczuk, Justin A. Ezekowitz, Michael Chan, Michael McDonald, Karen Harkness, Mustafa Toma, Robert S. McKelvie, Olivier Desplantie, Abdul Al-Hesaye, Shelley Zieroth, Ccs Hf Guidelines Primary, Haissam Haddad, University of British Columbia (UBC), University of Manitoba [Winnipeg], Lived Experience Partner [Toronto, ON, Canada] (LEP), Montreal Heart Institute - Institut de Cardiologie de Montréal, Hamilton Health Sciences, University of Alberta, University Health Network, Royal Alexandra Children's Hospital, McGill University Health Center [Montreal] (MUHC), McMaster University [Hamilton, Ontario], University of Waterloo [Waterloo], University of Calgary, Université de Sherbrooke (UdeS), University of Ottawa [Ottawa], St. Michael's Hospital, Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Dr. Georges-L.-Dumont University Hospital Centre (CHUDGLD), Western University [London, ON, Canada], University of Toronto, Saint Boniface General Hospital [Winnipeg, MA, Canada] (SBGH), University of Saskatchewan [Saskatoon] (U of S), Duke University [Durham], Centre Hospitalier Régional de Lanaudiere [Joliette, QC, Canada] (CHRDL), Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Université Laval [Québec] (ULaval), University of Colorado Anschutz [Aurora], Hôpital régional Chaleur [Bathurst, NB, Canada] (HRC), Université de Montréal (UdeM), QEII Health Sciences Centre [Halifax, NS, Canada] (HSC), Memorial University of Newfoundland = Université Memorial de Terre-Neuve [St. John's, Canada] (MUN), Writing Group, Canadian Heart Failure Society and the Canadian Cardiovascular Society Heart Failure Guidelines Panel, CCS HF Guidelines Primary and Secondary Panel., and leboeuf, Christophe
Subjects: lcsh:Diseases of the circulatory (Cardiovascular) system, Shared care, business.industry, MEDLINE, Capacity building, Review, Canadian Cardiovascular Society, Viewpoints, medicine.disease, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Nursing, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, lcsh:RC666-701, Heart failure, Health care, Ambulatory, medicine, Cardiology and Cardiovascular Medicine, business
Abstract: This joint Canadian Heart Failure Society and the CCS Heart Failure guidelines report has been developed to provide a pan-Canadian snapshot of the current state of clinic-based ambulatory heart failure (HF) care in Canada with specific reference to elements and processes of care associated with quality and high performing health systems. It includes the viewpoints of persons with lived experience, patient care providers, and administrators. It is imperative to build on the themes identified in this survey, through engaging all health care professionals, to develop integrated and shared care models that will allow better patient outcomes. Several patient and organizational barriers to care were identified in this survey, which must inform the development of regional care models and pragmatic solutions to improve transitions for this patient population. Unfortunately, we were unsuccessful in incorporating the perspectives of primary care providers and internal medicine specialists who provide the majority of HF care in Canada, which in turn limits our ability to comment on strategies for capacity building outside the HF clinic setting. These considerations must be taken into account when interpreting our findings. Engaging all HF care providers, to build on the themes identified in this survey, will be an important next step in developing integrated and shared care models known to improve patient outcomes. Résumé: Ce rapport conjoint des lignes directrices de la Société canadienne d'insuffisance cardiaque et de la Société canadienne de cardiologie (SCC) sur l'insuffisance cardiaque a été élaboré pour fournir un aperçu pancanadien de l'état actuel des soins ambulatoires de l'insuffisance cardiaque (IC) en clinique au Canada, en se référant spécifiquement aux éléments et aux processus de soins associés à des systèmes de santé très performants et de qualité. Il comprend les points de vue de personnes ayant une expérience vécue de l'IC, de prestataires de soins aux patients et d'administrateurs. Il est impératif de s'appuyer sur les thématiques identifiées dans cette enquête, en y engageant tous les professionnels de la santé, pour développer des modèles de soins intégrés et partagés qui permettront de meilleurs pronostics pour les patients. Plusieurs obstacles relatifs aux patients et organisationnels dont il faudra se soucier ont été identifiés dans cette enquête, qui doit servir de base à l'élaboration de modèles de soins régionaux et de solutions pragmatiques pour améliorer les transitions pour cette population de patients. Malheureusement, nous n'avons pas réussi à intégrer les points de vue des prestataires de soins primaires et des spécialistes en médecine interne qui fournissent la majorité des soins en IC au Canada, ce qui limite notre capacité à commenter les stratégies de renforcement des capacités en dehors du cadre des cliniques d’IC. Ces considérations doivent être prises en compte lors de l'interprétation de nos conclusions. L'engagement de tous les prestataires de soins de santé en IC à s'appuyer sur les thématiques identifiées dans cette enquête constituera une prochaine étape importante dans le développement de modèles de soins intégrés et partagés connus pour améliorer le pronostic des patients.
Published: 2020

30. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

Author: Lyon, Alexander R., Dent, Susan, Stanway, Susanna, Earl, Helena, Brezden‐Masley, Christine, Cohen‐Solal, Alain, Tocchetti, Carlo G., Moslehi, Javid, Groarke, John D., Bergler‐Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S., Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendirnathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G., Belenkov, Yury, Rosen, Stuart D., Iakobishvili, Zaza, Sverdlov, Aaron L., Hajjar, Ludhmila A., Macedo, Ariane V. S., Manisty, Charlotte, Ciardiello, Fortunato, Farmakis, Dimitrios, De Boer, Rudolf A., Skouri, Hadi, Suter, Thomas M., Cardinale, Daniela, Witteles, Ronald M., Fradley, Michael G., Herrmann, Joerg, Cornell, Robert F., Wechelaker, Ashutosh, Mauro, Michael J., Milojkovic, Dragana, Lavallade, Hugues, Ruschitzka, Frank, Coats, Andrew J. S., Seferovic, Petar M., Chioncel, Ovidiu, Thum, Thomas, Bauersachs, Johann, Andres, M. Sol, Wright, David J., López‐Fernández, Teresa, Plummer, Chris, Lenihan, Daniel, Imperial College London, Duke University [Durham], The Royal Marsden, University of Cambridge [UK] (CAM), Mount Sinai Hospital [Toronto, Canada] (MSH), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Naples Federico II = Università degli studi di Napoli Federico II, Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), Medizinische Universität Wien = Medical University of Vienna, Monash University [Melbourne], Shanghai Center for Plant Stress Biology [CAS] (PSC), Chinese Academy of Sciences [Beijing] (CAS), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Georg-August-University = Georg-August-Universität Göttingen, Hannover Medical School [Hannover] (MHH), Charles University [Prague] (CU), Georgetown University [Washington] (GU), University Health Network, University of Toronto, University of Pennsylvania, Massachusetts General Hospital [Boston], Sechenov First Moscow State Medical University, University College of London [London] (UCL), Tel Aviv University (TAU), University of Newcastle [Australia] (UoN), Universidade de São Paulo = University of São Paulo (USP), Università degli studi della Campania 'Luigi Vanvitelli' = University of the Study of Campania Luigi Vanvitelli, University of Cyprus [Nicosia] (UCY), University Medical Center Groningen [Groningen] (UMCG), American University of Beirut Faculty of Medicine and Medical Center (AUB), University of Bern, IRCCS Ospedale San Raffaele [Milan, Italy], Stanford University, Mayo Clinic [Rochester], Memorial Sloan Kettering Cancer Center (MSKCC), Hammersmith Hospital NHS Imperial College Healthcare, King's College Hospital (KCH), University hospital of Zurich [Zurich], University of Warwick [Coventry], Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS San Raffaele Pisana), University of Belgrade [Belgrade], Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu' [Bucharest, Romania], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Royal Brompton Hospital, Liverpool Heart and Chest Hospital NHS Trust [UK] (LH&CH), La Paz University Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), leboeuf, Christophe, Lyon, Alexander R, Dent, Susan, Stanway, Susanna, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo G, Moslehi, Javid, Groarke, John D, Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S, von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendirnathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G, Belenkov, Yury, Rosen, Stuart D, Iakobishvili, Zaza, Sverdlov, Aaron L, Hajjar, Ludhmila A, Macedo, Ariane V S, Manisty, Charlotte, Ciardiello, Fortunato, Farmakis, Dimitrio, De Boer, Rudolf A, Skouri, Hadi, Suter, Thomas M, Cardinale, Daniela, Witteles, Ronald M, Fradley, Michael G, Herrmann, Joerg, Cornell, Robert F, Wechelaker, Ashutosh, Mauro, Michael J, Milojkovic, Dragana, de Lavallade, Hugue, Ruschitzka, Frank, Coats, Andrew J S, Seferovic, Petar M, Chioncel, Ovidiu, Thum, Thoma, Bauersachs, Johann, Andres, M Sol, Wright, David J, López-Fernández, Teresa, Plummer, Chri, Lenihan, Daniel, Lyon, Alexander R., Brezden‐masley, Christine, Cohen‐solal, Alain, Tocchetti, Carlo G., Groarke, John D., Bergler‐klein, Jutta, Anker, Markus S., Haehling, Stephan, Neilan, Tomas G., Rosen, Stuart D., Sverdlov, Aaron L., Hajjar, Ludhmila A., Macedo, Ariane V. S., De Boer, Rudolf A., Suter, Thomas M., Witteles, Ronald M., Fradley, Michael G., Cornell, Robert F., Mauro, Michael J., Lavallade, Hugue, Coats, Andrew J. S., Seferovic, Petar M., Andres, M. Sol, Wright, David J., and López‐fernández, Teresa
Subjects: Male, Heart failure, Androgen Antagonists, Antineoplastic Agents, Middle Aged, Risk Assessment, Cardiotoxicity, Risk prediction, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Cardio-oncology, risk factor, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Cardiovascular Diseases, Heart Disease Risk Factors, Risk Factors, Neoplasms, Humans, Female, Aged
Abstract: This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for CML targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies. This article is protected by copyright. All rights reserved.
Published: 2020

31. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial

Author: Burkert, Pieske, Mahesh J, Patel, Cynthia M, Westerhout, Kevin J, Anstrom, Javed, Butler, Justin, Ezekowitz, Adrian F, Hernandez, Joerg, Koglin, Carolyn S P, Lam, Piotr, Ponikowski, Lothar, Roessig, Adriaan A, Voors, Christopher M, O'Connor, Paul W, Armstrong, Jian, Zhang, leboeuf, Christophe, Charité Campus Virchow-Klinikum (CVK), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Merck & Co. Inc. [Kenilworth, NJ, USA], University of Alberta, Duke University Medical Center, University of Mississippi Medical Center (UMMC), King‘s College London, University of Wrocław [Poland] (UWr), Bayer Pharma AG [Berlin], University Medical Center Groningen [Groningen] (UMCG), Duke University [Durham], VICTORIA Study Group: Imran Zainal Abidin, Dan Atar, M Cecilia Bahit, Juan Luis Arango Benecke, Edimar A Bocchi, Diana Bonderman, Myeong-Chan Cho, Chern-En Chiang, Alain Cohen-Solal, Martin Cowie, Frank Edelmann, Michele Emdin, Jorge Escobedo, Justin A Ezekowitz, Michael M Givertz, David M Kaye, Fernando Lanas, Johan Lassus, Basil S Lewis, Yury Lopatin, José López-Sendón, Lars H Lund, Kenneth McDonald, Vojtěch Melenovský, Arend Mosterd, Ebrahim Noori, M Ali Oto, Armando Lionel Godoy Palomino, Ileana L Piña, Piotr Ponikowski, Anne-Catherine Pouleur, Jens Refsgaard, Eugene Reyes, Clara Saldarriaga, Michele Senni, David Sim, David Siu, Karen Sliwa-Hähnle, Nancy K Sweitzer, Richard W Troughton, Hiroyuki Tsutsui, Dimitrios N Tziakas, Jose B Vazquez-Tanus, Jian Zhang., and Cardiovascular Centre (CVC)
Subjects: Male, 030204 cardiovascular system & hematology, Coronary artery disease, 0302 clinical medicine, Interquartile range, Natriuretic Peptide, Brain, Heart Failure/blood, Myocardial infarction, Prospective Studies, education.field_of_study, Framingham Risk Score, Ejection fraction, Atrial fibrillation, Heart failure with reduced ejection fraction, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Clinical trial, Treatment Outcome, STIMULATOR, ENALAPRIL, Cardiology, Female, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Population, Heterocyclic Compounds, 2-Ring, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, SOLUBLE GUANYLATE-CYCLASE, Humans, Soluble guanylate cyclase, Cyclic guanosine monophosphate, Protein Precursors, education, Heterocyclic Compounds, 2-Ring/therapeutic use, Aged, Heart Failure, business.industry, Pyrimidines/therapeutic use, Stroke Volume, medicine.disease, Peptide Fragments, Pyrimidines, Stroke Volume/physiology, Heart failure, Natriuretic Peptide, Brain/blood, business, Peptide Fragments/blood, Biomarkers, Biomarkers/blood, Follow-Up Studies
Abstract: International audience; Aim: Describe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.Methods and results: Key background characteristics were evaluated in 5050 patients randomized in VICTORIA and categorized into three cohorts reflecting their index worsening HF event. Differences within the VICTORIA population were assessed and compared with PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and COMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure). VICTORIA patients had increased risk of mortality and rehospitalization: New York Heart Association class (40% class III), atrial fibrillation (45%), diabetes (47%), hypertension (79%) and mean estimated glomerular filtration rate of 61.5 mL/min/1.73 m2 . Baseline standard of HF care was very good: 60% received triple therapy. Their N-terminal pro-B-type natriuretic peptide was 3377 pg/mL [interquartile range (IQR) 1992-6380]. Natriuretic peptides were 30% higher level in the 67% patients with HF hospitalization
Published: 2019

32. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions

Author: Aušra Kavoliūnienė, Carolyn S.P. Lam, Christian Mueller, Òscar Miró, Vera Regitz-Zagrosek, Aldo P. Maggioni, Alexandre Mebazaa, Alain Cohen-Solal, Adriaan A. Voors, Yuya Matsue, Katsuya Kajimoto, Jiri Parenica, Gregg C. Fonarow, W. Frank Peacock, Eiichi Akiyama, Johan Lassus, Dong-Ju Choi, Etienne Gayat, Ali Ahmed, Jelena Čelutkienė, Justina Motiejūnaitė, Justin A. Ezekowitz, Naoki Sato, Cardiovascular Centre (CVC), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lithuanian University of Health Sciences [Kaunas, Lithuania], Yokohama City University (YCU), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Research Center [Associazione Nazionale Medici Cardiologi Ospedalieri] (ANMCO Research Center), Associazione Nazionale Medici Cardiologi Ospedalieri [Firenze] (ANMCO), University of Basel (Unibas), Seoul National University Bundang Hospital (SNUBH), Lithuanian University of health Sciences [Kaunas], Vilnius University [Vilnius], University Hospital Brno, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Sekikawa Hospital [Tokyo, Japan] (SH), Nippon Medical School [Tokyo, Japan], University of Barcelona, Baylor College of Medicine (BCM), Baylor University, Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Boston University School of Medicine (BUSM), Boston University [Boston] (BU), King‘s College London, University of Alberta, Linköping University (LIU), University of California (UC), Service d'Anesthésie-Réanimation [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], and leboeuf, Christophe
Subjects: Male, medicine.medical_specialty, CONTEMPORARY MANAGEMENT, Asia, Prognosis, 030204 cardiovascular system & hematology, Lower risk, Ventricular Function, Left, EJECTION FRACTION, 03 medical and health sciences, AGE, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, ESC Report, Medicine, Humans, In patient, 030212 general & internal medicine, Prospective Studies, Registries, PREDICTORS, Heart Failure, Ejection fraction, business.industry, GENDER-RELATED DIFFERENCES, MORTALITY, Hazard ratio, Acute heart failure, Gender, Stroke Volume, medicine.disease, Biological sex, Comorbidity, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Clinical trial, Europe, Editorial, Heart failure, Acute Disease, Female, Cardiology and Cardiovascular Medicine, business
Abstract: Aims Recent data from national registries suggest that acute heart failure (AHF) outcomes might vary in men and women, however, it is not known whether this observation is universal. The aim of this study was to evaluate the association of biological sex and 1-year all-cause mortality in patients with AHF in various regions of the world. Methods and results We analysed several AHF cohorts including GREAT registry (22 523 patients, mostly from Europe and Asia) and OPTIMIZE-HF (26 376 patients from the USA). Clinical characteristics and medication use at discharge were collected. Hazard ratios (HRs) for 1-year mortality according to biological sex were calculated using a Cox proportional hazards regression model with adjustment for baseline characteristics (e.g. age, comorbidities, clinical and laboratory parameters at admission, left ventricular ejection fraction). In the GREAT registry, women had a lower risk of death in the year following AHF [HR 0.86 (0.79–0.94), P Conclusion Globally women with AHF have a lower 1-year mortality and less evidenced-based treatment than men. Differences among countries need further investigation. Our findings merit consideration when designing future global clinical trials in AHF.
Published: 2019

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

32 results on '"Leboeuf, Christophe"'

1. Genomics applied to the treatment of breast cancer

2. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)

3. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials

4. Iron deficiency in pulmonary arterial hypertension: perspectives

5. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure with Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial

6. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

7. proANP Metabolism Provides New Insights Into Sacubitril/Valsartan Mode of Action

8. Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?

9. Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol

10. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure

11. Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology

12. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis

13. Mega-trials in heart failure

14. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

15. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

16. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF

17. Recent advances in cardio-oncology

18. Determinants of left atrioventricular coupling index: The Multi-Ethnic Study of Atherosclerosis (MESA)

19. Left Atrioventricular Coupling Index to Predict Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis

20. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: The results of the AFFIRM-AHF study

21. Amended STRONG-HF study design

22. Acute heart failure treatment: a light at the end of the tunnel?

23. Right ventricular function and iron deficiency in acute heart failure

24. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

25. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

26. New treatments for heart failure and exercise capacity

27. Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors

28. Characterization of non‐response to cardiac resynchronization therapy by post‐procedural computed tomography

29. The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey

31. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial

32. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

32 results on '"Leboeuf, Christophe"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources